“3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s78. doi:10.25251/skin.6.supp.78.